Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab + Blinatumomab in R/R B-ALL
NCT03160079Phase 2Completed
- Sponsor
- University of California, San Diego
- Start
- Aug 2017
- Primary completion
- Dec 2021
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in B cell acute lymphoblastic leukemia (B-ALL), sponsored by University of California, San Diego. Started Aug 2017; status: completed.
02
Drugs
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on NCT03160079.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03160079.